Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy

SIMPLE SUMMARY: Tamoxifen is an important adjuvant endocrine therapy in estrogen receptor (ER)-positive breast cancer patients. It is mainly catalyzed by the enzyme CYP2D6 into the most active metabolite endoxifen. Genetic variation in the CYP2D6 gene influences endoxifen formation and thereby poten...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Main Authors: Mulder, Tessa A. M., de With, Mirjam, del Re, Marzia, Danesi, Romano, Mathijssen, Ron H. J., van Schaik, Ron H. N.
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2021
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7917604/
https://ncbi.nlm.nih.gov/pubmed/33673305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13040771
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares